Skip to content

Trevi Therapeutics

US · TRVI #2810 by market cap Listed 2019
13.35 -0.37 -2.70%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    Clear Street Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $29
    Market Newswire · 2026/5/8
  • Rating change
    H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $21
    Market Newswire · 2026/5/8
  • Rating change
    Needham Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23
    Market Newswire · 2026/7/17
  • Rating change
    Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $30
    Market Newswire · 2026/5/8
  • Rating change
    H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $24
    Market Newswire · 2026/7/20
  • Rating change
    Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24
    Market Newswire · 2026/5/8
  • Rating change
    JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $28
    Market Newswire · 2026/8/14
  • Rating change
    Trevi Therapeutics (TRVI) Receives a New Rating From B. Riley Securities
    TipRanks · 2026/8/7
  • Trevi Therapeutics (TRVI.US) will release its financial report after the market close on November 9
    Market Newswire · 2026/11/4
  • H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24
    Market Newswire · 2026/11/10
  • Rating change
    Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $25
    Market Newswire · 2026/8/7
  • Rating change
    BMO Capital Initiates Trevi Therapeutics(TRVI.US) With Buy Rating, Announces Target Price $36
    Market Newswire · 2026/7/21
  • Rating change
    Trevi Therapeutics (TRVI) Receives a Buy From H.C. Wainwright
    TipRanks · 2026/9/22
  • Rating change
    JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $28
    Market Newswire · 2026/10/23
  • BMO Capital Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $36
    Market Newswire · 2026/11/10
  • A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $23 to $36
    Market Newswire · 2026/11/11
  • Rating change
    Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23
    Market Newswire · 2026/8/10
  • Rating change
    Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $23
    Market Newswire · 2026/8/7
  • Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/11/10
  • Rating change
    A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $23 to $40
    Market Newswire · 2026/8/8
  • BMO Capital Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $36
    Market Newswire · 2026/10/7
  • Rating change
    A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $18 to $23
    Market Newswire · 2026/5/6
  • Rating change
    Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $30
    Market Newswire · 2026/8/7
  • H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24
    Market Newswire · 2026/9/22
  • Rating change
    JonesTrading Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24
    Market Newswire · 2026/5/7

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.

Trevi Therapeutics discussion 0 comments

Add a comment